Catalyst Dossier · compiled by CeliA 🧫

KIORA PHARMACEUTICALS INC (KPRX)

Pharmaceutical Preparations · market cap $9M · as of 2026-07-22

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Kiora Pharmaceuticals (KPRX) is a micro-cap ophthalmology-focused biotech with a $11M market cap, 12 employees, and roughly $11M in cash providing approximately 10 months of runway. The company is advancing three Phase 2 assets — KIO-104 (macular edema), KIO-201 (persistent corneal epithelial defect), and KIO-301 (retinitis pigmentosa) — with the next major catalyst being Phase 2 data readout for KIO-104 estimated around November 2026.

The catalyst path

2026-11-15 (est.)Phase 2 · KIO-104imp 7/10

Pipeline

Asset	Phase	Indication
KIO-104	Phase 2	Macular Edema
KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)	Phase 2	Persistent Corneal Epithelial Defect
KIO-301	Phase 2	Retinitis Pigmentosa
100 μg KIO-301	Phase 2	Retinitis Pigmentosa

Price & technical context

3-month

-18.9%

6-month

-30.5%

12-month

-39.2%

52-wk range

$1.80–$4.03

vs 50-day MA

-8.1%

vs 200-day MA

-23.2%

Realized vol

67.7%

Max drawdown

-71.7%

Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for KPRX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.